The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: A double-blind, randomized, placebo-controlled trial

Drug Design, Development and Therapy

Volumn 12, Issue , 2018, Pages 735-742

  Aziz, Tavga Ahmed ^a   Hussain, Saad Abdulrahman ^b   Mahwi, Taha Othman ^a   Ahmed, Zheen Aorahman ^a   Rahman, Heshu Sulaiman ^a,c,d   Rasedee, Abdullah ^d  

^a UNIVERSITY OF SULAIMANI   (Iraq)

^b BILAD ALRAFIDAIN UNIVERSITY COLLEGE   (Iraq)

^c KOMAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Iraq)

^d UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

BMI; Ginkgo biloba extract; Glycemic control; Insulin resistance; Metformin; T2DM

Indexed keywords

GINKGO BILOBA EXTRACT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; PLANT EXTRACT;

ADJUVANT THERAPY; ADULT; ANTHROPOMETRIC PARAMETERS; ANTIDIABETIC ACTIVITY; ARTICLE; BODY MASS; CONTROLLED STUDY; DIETARY SUPPLEMENT; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT OUTCOME; VISCERAL ADIPOSITY INDEX; WAIST CIRCUMFERENCE; AGED; CLINICAL TRIAL; PLACEBO EFFECT;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PLACEBO EFFECT; PLANT EXTRACTS;

EID: 85045899568     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S157113     Document Type: Article

References (33)

1. Padberg I, Peter E, González-Maldonado S, et al. A new metabolomic signature in type-2 diabetes mellitus and its pathophysiology. PLoS One. 2014; 9(1): e85082.
2. Chen Y, Zhou L, Xu Y, Shen H, Niu J. A study on the relationship between genetic and environmental factors of type 2 diabetes mellitus in humans. Zhonghua Yu Fang Yi Xue Za Zhi. 2002; 36(3): 191-194.
3. Prevention CfDC. Diabetes Report Card, 2014. Atlanta, GA, USA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2015.
4. Krentz AJ, Bailey CJ. Oral antidiabetic agents. Drugs. 2005; 65(3): 385-411.
5. Upadhyay J, Polyzos SA, Perakakis N, et al. Pharmacotherapy of type 2 diabetes: an update. Metabolism. 2017; 78: 13-42.
6. Hedrington MS, Davis SN. Discontinued drug therapies to treat diabetes in 2015. Expert Opin Investig Drugs. 2017; 26(2): 219-225.
7. Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013; 12(2): 153-175.
8. Habeck M. Diabetes Treatments Get Sweet Help from Nature. Nat Med. 2003; 9(10): 1228.
9. Rizvi SI, Matteucci E, Atukeren P. Traditional medicine in management of type 2 diabetes mellitus. J Diabetes Res. 2013; 2013: 580823.
10. Mohanta TK, Tamboli Y, Zubaidha PK. Phytochemical and medicinal importance of Ginkgo biloba L. Nat Prod Res. 2014; 28(10): 746-752.
11. Boghdady NEl. Antioxidant and antiapoptotic effects of proanthocyanidin and ginkgo biloba extract against doxorubicin-induced cardiac injury in rats. Cell Biochem Funct. 2013; 31(4): 344-351.
12. Zhao Q, Gao C, Cui Z. Ginkgolide A reduces inflammatory response in high-glucose-stimulated human umbilical vein endothelial cells through STAT3-mediated pathway. Int Immunopharmacol. 2015; 25(2): 242-248.
13. Biesinger S, Michaels HA, Quadros AS, et al. A combination of isolated phytochemicals and botanical extracts lowers diastolic blood pressure in a randomized controlled trial of hypertensive subjects. Eur J Clin Nutr. 2016; 70(1): 10-16.
14. American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care. 2013; 36(4): 1033-1046.
15. Amato MC, Giordano C, Galia M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010; 33(4): 920-922.
16. Azevedo M, Alla S. Diabetes in sub-saharan Africa: Kenya, Mali, Mozambique, Nigeria, South Africa and Zambia. Int J Diabetes Dev Ctries. 2008; 28(4): 101-108.
17. Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich). 2011; 13(4): 244-251.
18. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014; 37(3): 887-887.
19. Lian F, Tian J, Chen X, et al. The efficacy and safety of Chinese herbal medicine Jinlida as add-on medication in type 2 diabetes patients ineffectively managed by metformin monotherapy: a double-blind, randomized, placebo-controlled, multicenter trial. PLoS One. 2015; 10(6): e0130550.
20. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002; 137(1): 25-33.
21. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009; 32(9): 1649-1655.
22. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000; 283(13): 1695-1702.
23. Ji L-N, Lu J-M, Guo X-H, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013; 13(1): 602.
24. Chang HY, Wallis M, Tiralongo E. Use of complementary and alternative medicine among people living with diabetes: literature review. J Adv Nurs. 2007; 58(4): 307-319.
25. Rhee K-J, Lee CG, Kim SW, Gim D-H, Kim H-C, Jung BD. Extract of Ginkgo Biloba ameliorates streptozotocin-induced type 1 diabetes mellitus and high-fat diet-induced type 2 diabetes mellitus in mice. Int J Med Sci. 2015; 12(12): 987-994.
26. Cheng D, Liang B, Li Y. Antihyperglycemic effect of Ginkgo biloba extract in streptozotocin-induced diabetes in rats. Biomed Res Int. 2012; 2013: 162724.
27. Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic β-cell function in response to glucose loading in normal glucose tolerant individuals. J Clin Pharmacol. 2000; 40(6): 647-654.
28. Banin RM, Hirata BKS, Andrade IS, et al. Beneficial effects of Ginkgo biloba extract on insulin signaling cascade, dyslipidemia, and body adiposity of diet-induced obese rats. Braz J Med Biol Res. 2014; 47(9): 780-788.
29. Zhou L, Meng Q, Qian T, Yang Z. Ginkgo biloba extract enhances glucose tolerance in hyperinsulinism-induced hepatic cells. J Nat Med. 2011; 65(1): 50-56.
30. Dell’Agli M, Bosisio E. Biflavones of Ginkgo biloba stimulate lipolysis in 3T3-L1 adipocytes. Planta Med. 2002; 68(1): 76-79.
31. Kang H. Hypocholesterolemic effect of Ginkgo biloba seeds extract from high fat diet mice. Biomed Sci Lett. 2017; 23(2): 138-143.
32. Hirata BKS, de Souza Figueiredo J, Telles MM. Ginkgo biloba extract (GbE): promising therapeutic perspective to treat obesity and diabetes. Curr Res Diabetes Obes J. 2017; 3(2): 001-003.
33. Hussain SA. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. J Med Food. 2007; 10(3): 543-547.